Cargando…

258 A Novel Therapeutical Option in Resistant Ganglionar and Cutaneous Tuberculosis

BACKGROUND: Transfer factor was first described in 1955 and constitutes a Dialyzable Leukocyte Extract. It has been widely used in several infectious diseases and malignancies with satisfactory results. Although not yet fully clarified, among the mechanisms of action the most accepted is the enhance...

Descripción completa

Detalles Bibliográficos
Autores principales: Vidal, Laura, Palafox, Damián, Hernández-Lagunes, Araceli, Palafox, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization Journal 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513134/
http://dx.doi.org/10.1097/01.WOX.0000412015.91855.71
_version_ 1782251883889426432
author Vidal, Laura
Palafox, Damián
Hernández-Lagunes, Araceli
Palafox, José
author_facet Vidal, Laura
Palafox, Damián
Hernández-Lagunes, Araceli
Palafox, José
author_sort Vidal, Laura
collection PubMed
description BACKGROUND: Transfer factor was first described in 1955 and constitutes a Dialyzable Leukocyte Extract. It has been widely used in several infectious diseases and malignancies with satisfactory results. Although not yet fully clarified, among the mechanisms of action the most accepted is the enhancement of the cellular immunity. METHODS: We tested transfer factor in a 1 year old and 3 months patient diagnosed with Ganglionar Tuberculosis. 1 week after the administrarion of the Bacillus Calmette-Guérin vaccination, the present developed fever, cervical, submandibular, supraclavicular, inguinal and axillary lymphadenopathy. Later on the patient devoloped cutaneous clinical manifestations of tuberculosis such as scrofuloderma, fistulas, hypertrophic scars and ultimately, queloids. The patient had previously undergone short-term strictly supervised treatment for tuberculosis with very poor results. When the treatment was first administered, the patient had the following data: Total White Blood Count 12.9 Lymphocytes: 29% (12–46) CD3: 26.3% (59–90) T helper Cells (CD3/CD4) 21.6% (42–58) Cytotoxic T cells (CD3/CD8) 5.1% (17–33) Natural Killer Cells (CD56) 2.1% (3–7) B cells (CD19) 67.6 % (0–10). RESULTS: At the end of the treatment, the patient´s immune system was enhanced in terms of cell count and improval of skin manifestations. Total White Blood Count 6.5 Lymphocytes: 51.3% CD3: 48.5% T helper cells (CD3/CD4) 31.2% Cytotoxic T Cells (CD3/CD8) 14.6% Natural Killer cells (CD56) 12.2% B cells (CD19) 985%. Cicatrization process was improved, with involution of skin lesions os scrofuloderma and fistulas. Lymphadenopathy was no longer encountered. We have followed the patient for a year and half and no relapses have been encountered. CONCLUSIONS: We consider Transfer Factor a valuable option as adyuvant therapy in cases of ganglionar and cutaneous tuberculosis refractory to conventional treatments. To our knowledge, this is the first report of a case of the disease treated satisfactorily with transfer factor.
format Online
Article
Text
id pubmed-3513134
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher World Allergy Organization Journal
record_format MEDLINE/PubMed
spelling pubmed-35131342012-12-21 258 A Novel Therapeutical Option in Resistant Ganglionar and Cutaneous Tuberculosis Vidal, Laura Palafox, Damián Hernández-Lagunes, Araceli Palafox, José World Allergy Organ J Abstracts of the XXII World Allergy Congress BACKGROUND: Transfer factor was first described in 1955 and constitutes a Dialyzable Leukocyte Extract. It has been widely used in several infectious diseases and malignancies with satisfactory results. Although not yet fully clarified, among the mechanisms of action the most accepted is the enhancement of the cellular immunity. METHODS: We tested transfer factor in a 1 year old and 3 months patient diagnosed with Ganglionar Tuberculosis. 1 week after the administrarion of the Bacillus Calmette-Guérin vaccination, the present developed fever, cervical, submandibular, supraclavicular, inguinal and axillary lymphadenopathy. Later on the patient devoloped cutaneous clinical manifestations of tuberculosis such as scrofuloderma, fistulas, hypertrophic scars and ultimately, queloids. The patient had previously undergone short-term strictly supervised treatment for tuberculosis with very poor results. When the treatment was first administered, the patient had the following data: Total White Blood Count 12.9 Lymphocytes: 29% (12–46) CD3: 26.3% (59–90) T helper Cells (CD3/CD4) 21.6% (42–58) Cytotoxic T cells (CD3/CD8) 5.1% (17–33) Natural Killer Cells (CD56) 2.1% (3–7) B cells (CD19) 67.6 % (0–10). RESULTS: At the end of the treatment, the patient´s immune system was enhanced in terms of cell count and improval of skin manifestations. Total White Blood Count 6.5 Lymphocytes: 51.3% CD3: 48.5% T helper cells (CD3/CD4) 31.2% Cytotoxic T Cells (CD3/CD8) 14.6% Natural Killer cells (CD56) 12.2% B cells (CD19) 985%. Cicatrization process was improved, with involution of skin lesions os scrofuloderma and fistulas. Lymphadenopathy was no longer encountered. We have followed the patient for a year and half and no relapses have been encountered. CONCLUSIONS: We consider Transfer Factor a valuable option as adyuvant therapy in cases of ganglionar and cutaneous tuberculosis refractory to conventional treatments. To our knowledge, this is the first report of a case of the disease treated satisfactorily with transfer factor. World Allergy Organization Journal 2012-02-17 /pmc/articles/PMC3513134/ http://dx.doi.org/10.1097/01.WOX.0000412015.91855.71 Text en Copyright © 2012 by World Allergy Organization
spellingShingle Abstracts of the XXII World Allergy Congress
Vidal, Laura
Palafox, Damián
Hernández-Lagunes, Araceli
Palafox, José
258 A Novel Therapeutical Option in Resistant Ganglionar and Cutaneous Tuberculosis
title 258 A Novel Therapeutical Option in Resistant Ganglionar and Cutaneous Tuberculosis
title_full 258 A Novel Therapeutical Option in Resistant Ganglionar and Cutaneous Tuberculosis
title_fullStr 258 A Novel Therapeutical Option in Resistant Ganglionar and Cutaneous Tuberculosis
title_full_unstemmed 258 A Novel Therapeutical Option in Resistant Ganglionar and Cutaneous Tuberculosis
title_short 258 A Novel Therapeutical Option in Resistant Ganglionar and Cutaneous Tuberculosis
title_sort 258 a novel therapeutical option in resistant ganglionar and cutaneous tuberculosis
topic Abstracts of the XXII World Allergy Congress
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513134/
http://dx.doi.org/10.1097/01.WOX.0000412015.91855.71
work_keys_str_mv AT vidallaura 258anoveltherapeuticaloptioninresistantganglionarandcutaneoustuberculosis
AT palafoxdamian 258anoveltherapeuticaloptioninresistantganglionarandcutaneoustuberculosis
AT hernandezlagunesaraceli 258anoveltherapeuticaloptioninresistantganglionarandcutaneoustuberculosis
AT palafoxjose 258anoveltherapeuticaloptioninresistantganglionarandcutaneoustuberculosis